Jenne P. Ingrassia, BA; Muhammad Haisum Maqsood, MD; Joel M. Gelfand, MD; et al.
free access
JAMA Dermatol. 2024;160(1):28-36. doi:10.1001/jamadermatol.2023.4090
This systematic review and meta-analysis assesses the risk of all-cause mortality, major adverse cardiovascular events, and venous thromboembolism (VTE) with JAK inhibitors in patients with dermatologic conditions.
Marie-Charlotte Brüggen, MD, PhD; Sarah Walsh, MB, BCh, BMedSci; M. Milad Ameri, MS; et al.
free access
JAMA Dermatol. 2024;160(1):37-44. doi:10.1001/jamadermatol.2023.4450
This Delphi consensus exercise aims to reach an international expert consensus on the diagnostic workup, severity assessment, and treatment of patients with drug reaction with eosinophilia and systemic symptoms.
Ghida El-Banna, MD, MPP; Shawheen Justin Rezaei, MPhil; Michelle Chang, BA; et al.
free access
JAMA Dermatol. 2024;160(1):45-53. doi:10.1001/jamadermatol.2023.4439
This qualitative mixed-methods study explores how Muslim patients in the US perceive their dermatology care.
Nicole Kye Wen Tan; Adelina Tang; Neil Chen Yi Lun MacAlevey; et al.
open access
JAMA Dermatol. 2024;160(1):54-62. doi:10.1001/jamadermatol.2023.4579
This meta-analysis clarifies the risk of suicide and psychiatric disorders among isotretinoin users.
Hakim Ben Abdallah, MD; Anne Bregnhøj, MD; Thomas Emmanuel, MD; et al.
open access
JAMA Dermatol. 2024;160(1):63-70. doi:10.1001/jamadermatol.2023.4800
This parallel-design double-blind trial examines the efficacy and safety of the heat shock protein 90 inhibitor RGRN-305 in patients with hidradenitis suppurativa.
Ali Al-Janabi, MA (Cantab); Oras A. Alabas, PhD; Zenas Z. N. Yiu, PhD; et al.
open access
JAMA Dermatol. 2024;160(1):71-79. doi:10.1001/jamadermatol.2023.4846
This cohort study examines which biologic drug classes and factors are associated with risk of paradoxical eczema in patients with psoriasis treated with biologics.
Keshavamurthy Vinay, MD, DNB; Sheetanshu Kumar, MD; Anubha Dev, MD, DNB; et al.
JAMA Dermatol. 2024;160(1):80-87. doi:10.1001/jamadermatol.2023.4889
This randomized clinical trial evaluates the efficacy and safety of oral acitretin plus topical triamcinolone acetonide, 0.1%, compared with triamcinolone acetonide monotherapy in patients with symptomatic oral lichen planus.